AMPK

Nimbus Therapeutics Announces Expansion of Its Immunology Drug Discovery Pipeline

Retrieved on: 
Friday, January 5, 2024

Nimbus Therapeutics , LLC (“Nimbus Therapeutics” or “Nimbus”), a biotechnology company that designs and develops breakthrough medicines through its powerful computational drug discovery engine, announced the advancement and expansion of its pipeline with the addition of discovery programs targeting innate immunity pathways.

Key Points: 
  • Nimbus Therapeutics , LLC (“Nimbus Therapeutics” or “Nimbus”), a biotechnology company that designs and develops breakthrough medicines through its powerful computational drug discovery engine, announced the advancement and expansion of its pipeline with the addition of discovery programs targeting innate immunity pathways.
  • "Building on the success of our TYK2 program, we are broadening our drug discovery engine to unlock new difficult-to-drug targets with compelling biology,” said Peter Tummino, Ph.D., Chief Scientific Officer of Nimbus.
  • “SIK and cGAS are critical targets in highly prevalent diseases that are well suited to Nimbus’ structure-based drug design approach.
  • Nimbus continues to expand its platform capabilities with ongoing investments in cutting-edge technology for drug discovery.

Inhibitor Therapeutics, Inc. Exclusive License with Johns Hopkins University

Retrieved on: 
Wednesday, December 13, 2023

TAMPA, Fla., Dec. 13, 2023 /PRNewswire/ -- Inhibitor Therapeutics, Inc. ("Inhibitor") (OTCQB: INTI) has entered into an exclusive, worldwide licensing agreement (the "License") with Johns Hopkins University (JHU) for their U.S Patent 8,980,930 (Canada Patent 2,572,223) "New Angiogenesis Inhibitors". Angiogenesis Inhibitors, as described by the National Cancer Institute, are unique cancer fighting agents as they block the growth of blood vessels that support tumor growth rather than blocking the growth of the tumor cells themselves. Inventors affiliated with JHU developed this patent, listing Itraconazole as an Active Pharmaceutical Ingredient (API) that has anti-angiogenic properties.

Key Points: 
  • TAMPA, Fla., Dec. 13, 2023 /PRNewswire/ -- Inhibitor Therapeutics, Inc. ("Inhibitor") (OTCQB: INTI) has entered into an exclusive, worldwide licensing agreement (the "License") with Johns Hopkins University (JHU) for their U.S Patent 8,980,930 (Canada Patent 2,572,223) "New Angiogenesis Inhibitors".
  • Inventors affiliated with JHU developed this patent, listing Itraconazole as an Active Pharmaceutical Ingredient (API) that has anti-angiogenic properties.
  • Inhibitor believes the License is a mutually beneficial agreement, yielding a modest annual royalty rate with milestone payments typical to such a license.
  • A total of 13 new 'surgically eligible' lesions across 8 of the 38 patients developed over the duration of the study.

HighTide Therapeutics Inc. is Invited to Present at the 7th Edition of the Future Investment Initiative (FII): The New Compass, in Riyadh, Saudi Arabia

Retrieved on: 
Friday, October 27, 2023

The rising burden of aging-related diseases has become an urgent global health challenge that requires immediate attention.

Key Points: 
  • The rising burden of aging-related diseases has become an urgent global health challenge that requires immediate attention.
  • Recent advances in anti-aging research and big data empower a more holistic approach to understanding and reversing human aging with evidence suggests that slowing down aging can substantially improve quality of life.
  • The FII Conference, hosted by the Future Investment Initiative (FII) Institute, has been held for seven consecutive years and has developed into one of the most important economic and investment forums in the Middle East.
  • This year's conference (FII7) was attended exclusively by FII Institute members, strategic partners, decision-makers, and international leaders, and is expected to draw 5,000 delegates attending sessions covering a wide variety of issues with global impact.

Biolexis Therapeutics launches subsidiary Metabolexis to develop novel oral medicines for Obesity and Type 2 Diabetes to improve human longevity

Retrieved on: 
Thursday, October 26, 2023

AMERICAN FORK, Utah, Oct. 26, 2023 /PRNewswire/ -- Biolexis Therapeutics, a clinical-stage AI-enabled drug discovery company, today announced the launch of Metabolexis, a new pipeline company developing three targeted oral small molecules for the treatment of Obesity and Type 2 Diabetes, with the potential to improve human Longevity.

Key Points: 
  • Metabolexis focuses on GLP-1 weight loss and type 2 diabetic drug discoveries to improve accessibility and meet unprecedented demand.
  • AMERICAN FORK, Utah, Oct. 26, 2023 /PRNewswire/ -- Biolexis Therapeutics, a clinical-stage AI-enabled drug discovery company, today announced the launch of Metabolexis, a new pipeline company developing three targeted oral small molecules for the treatment of Obesity and Type 2 Diabetes, with the potential to improve human Longevity.
  • The World Health Organization estimates 650 million obese and 537 million Type 2 Diabetic patients worldwide.
  • The World Obesity Federation predicts that 51% of the world — more than 4 billion people — will be obese or overweight within the next 12 years.

Poxel Announces its Participation at Upcoming Scientific Conference

Retrieved on: 
Monday, October 2, 2023

POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced that it will participate at the upcoming 12th International Meeting on AMPK on October 4th, 2023.

Key Points: 
  • POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced that it will participate at the upcoming 12th International Meeting on AMPK on October 4th, 2023.
  • Sophie Bozec, Executive Vice President, R&D Pharmacology and Scientific Communication at Poxel, will host a virtual presentation on “Direct AMPK Activation: From Preclinical to Clinical.
  • Perspectives in Rare Metabolic Diseases”.
  • The presentation will review Poxel’s molecule PXL770, which is a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, focused on rare diseases treatment, including adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD).

Nimbus Therapeutics Secures $210M Private Financing to Advance Next Wave of Tech-Enabled Small Molecule Medicines

Retrieved on: 
Wednesday, September 6, 2023

Nimbus Therapeutics , LLC ("Nimbus Therapeutics” or “Nimbus”), a clinical-stage company that designs and develops breakthrough medicines through its powerful computational drug discovery engine, today announced the closing of a $210 million private financing to advance its next wave of tech-enabled small molecule medicines.

Key Points: 
  • Nimbus Therapeutics , LLC ("Nimbus Therapeutics” or “Nimbus”), a clinical-stage company that designs and develops breakthrough medicines through its powerful computational drug discovery engine, today announced the closing of a $210 million private financing to advance its next wave of tech-enabled small molecule medicines.
  • “We’re proud to have built an R&D organization that is a paradigm of excellence in small molecule drug discovery and development.
  • Nimbus will continue the ongoing clinical development of NDI-101150, a hematopoietic progenitor kinase 1 (HPK1) inhibitor, in patients with solid tumors.
  • “Nimbus has demonstrated its ability to advance early science through to successful product development multiple times.

Poxel Announces Upcoming Participation at the H.C. Wainwright 2nd Annual Kidney Conference

Retrieved on: 
Tuesday, July 18, 2023

POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its participation at the upcoming H.C. Wainwright 2nd Annual Kidney Conference , to be held virtually on July 25, 2023.

Key Points: 
  • POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its participation at the upcoming H.C. Wainwright 2nd Annual Kidney Conference , to be held virtually on July 25, 2023.
  • Thomas Kuhn, CEO, and members of the management team of Poxel, will be available for one-on-one virtual meetings on July 25, 2023.
  • The Company’s virtual presentation is scheduled the same day at 9:30 am ET (3.30 pm CEST) and will focus on PXL770, a novel, first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, for the treatment of autosomal dominant polycystic kidney disease (ADPKD).

NephroDI Therapeutics Enters Agreement to Develop a First-in-Class Treatment for a Genetic, Rare Disease of the Kidneys

Retrieved on: 
Thursday, June 22, 2023

NDI is a rare genetic kidney condition that affects individuals from birth, causing them to produce up to 20 liters of urine per day.

Key Points: 
  • NDI is a rare genetic kidney condition that affects individuals from birth, causing them to produce up to 20 liters of urine per day.
  • Later studies are anticipated to include affected individuals, providing an opportunity for early evidence of target engagement through increases in urine concentrating ability.
  • “The NDI, renal, and nephrology experts now collaborating across NephroDI, MSRD, and Otsuka are uniquely positioned to embark on the next phase of development for a potential, novel NDI treatment.
  • This team is driven by the opportunity to bring a first-in-class treatment to these patients and their families.”

Pan-Biome Pharmaceuticals, a startup focused on age-related diseases and increasing human healthspan, reports positive results in a preclinical trial of colitis

Retrieved on: 
Tuesday, April 25, 2023

We have found that the compound demonstrates selective antimicrobial activity and has the ability to modulate the gut microbiome in mice.

Key Points: 
  • We have found that the compound demonstrates selective antimicrobial activity and has the ability to modulate the gut microbiome in mice.
  • Most age-related diseases are accompanied by chronic low-grade inflammation (Inflammaging), resulting in higher levels of pro-inflammatory cytokines in the bloodstream.
  • Pan-Biome’s lead compound activates anti-inflammatory cytokine IL-10 and inhibits the major pro-inflammatory cytokines TNF-a, IL-1b, and IL-6.
  • Pan-Biome CSO Dr. Poul Sorensen: “While we are still working out the mechanism, our compound most likely optimizes mitochondrial functionality.

LifeQ Study, Published in bioRxiv, Finds Wearables Measure Biological Aging

Retrieved on: 
Monday, April 17, 2023

ATLANTA, April 17, 2023 /PRNewswire/ -- LifeQ, the company that uses globally-recognized watch brands to gather personalized, clinical-grade data, announced the results of its groundbreaking new study—Wearable-ome meets epigenome: A novel approach to measuring biological age with wearable devices, published in bioRxiv—revealing clear associations between wearable-derived behavioral and physiological features and the methylation of specific genes in pathways relating to the aging process.

Key Points: 
  • Wearable devices offer a non-invasive, continuous measure of physiological and behavioral features and how they pertain to aging."
  • For the LifeQ study, LifeQ-enabled wearables were used to measure behavior and its impacted physiological states, and DNA methylation levels were determined using the Illumina EPIC array.
  • "Biological aging is driven by epigenetic changes which can be measured by blood and DNA analysis," stated Dr. Deffur.
  • LifeQ-enabled wearables may also monitor and quantify various physiological biomarkers that correlate with life expectancy and the rate of biological aging.